Hsiu-chiung Yang
Biopharmaceutical R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Journal: International journal of molecular sciences
Published: April 21, 2022
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
Journal: Cardiovascular drugs and therapy
Published: August 19, 2021
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Journal: Cardiovascular drugs and therapy
Published: April 27, 2020
Deriving functional human enteroendocrine cells from pluripotent stem cells.
Journal: Development (Cambridge, England)
Published: March 21, 2018
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Journal: Cardiovascular drugs and therapy
Published: March 07, 2018
Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences.
Journal: Journal of medicinal chemistry
Published: November 01, 2017
Structural basis for GPR40 allosteric agonism and incretin stimulation.
Journal: Nature communications
Published: May 16, 2017
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Journal: Cardiovascular drugs and therapy
Published: April 28, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026